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Abstract	
Background	and	objectives:	Our	aim	was	to	use	a	national	electronic	AKI	alert,	
to	define	 the	 incidence	and	outcome	of	all	episodes	of	community	and	hospital	
acquired	adult	AKI	(AKI).	
Design,	 setting,	 participants	 and	 measurements:	 A	 prospective	 national	
cohort	study	was	undertaken	in	a	population	of	3.06	million.		Data	was	collected	
between	March	2015	and	August	2015.	 	All	 cases	of	 adult	 (≥18yrs	of	 age)	AKI	
were	identified	to	define	the	incidence	and	outcome	of	all	episodes	of	community	
and	hospital	acquired	AKI	in	adults.	Mortality	and	renal	outcomes	were	assessed	
at	90	days.		
Results:	 There	 were	 a	 total	 of	 31,601	 alerts,	 representing	 17,689	 incident	
episodes	 giving	 an	 incidence	 of	 AKI	 of	 577/100,000	 population.	 Community	
acquired	AKI	accounted	for	49.3%	of	all	incident	episodes,	and	42%	occurred	in	
the	 context	 of	 pre-existing	 CKD	 (CKDEpi	 eGFR).	 90-day	 mortality	 rate	 was	
25.6%.	 	 23.7%	 of	 episodes	 progressed	 to	 a	 higher	 AKI	 stage	 than	 the	 stage	
associated	with	the	alert.	AKI	e-alert	stage	and	peak	AKI	stage	were	associated	
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with	mortality,	and	mortality	was	significantly	higher	for	hospital	acquired	AKI	
compared	 to	 alerts	 generated	 in	 a	 community	 setting.	 	 Among	 patients	 who	
survived	 to	90	days	 following	 the	AKI	e-alert,	 those	who	were	not	hospitalized	
had	a	lower	rate	of	renal	recovery	and	a	greater	likelihood	of	developing	an	eGFR	
<60ml/min/1.73m2	for	the	first	time,	which	may	be	indicative	of	development	of	
de	novo	CKD.		
Conclusion:	 The	 reported	 incidence	 of	 AKI	 is	 far	 greater	 than	 previously	
reported	 incidence	 in	 studies	 reliant	 on	 clinical	 identification	 of	 adult	 AKI	 or	
hospital	coding	data.	Although	an	e-alert	system	is	IT	driven	and	therefore	lacks	
“intelligence”	and	clinical	context,	this	data	can	be	used	to	identify	deficiencies	in	
care,	guide	the	development	of	appropriate	intervention	strategies	and	provide	a	
baseline	against	which	the	effectiveness	of	these	interventions	may	be	measured.			
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Introduction	
The	 reported	 incidence	 of	 AKI	 varies	 depending	 on	 its	 definition,	 the	 clinical	
setting	in	which	it	is	detected,	and	the	population	studied.	The	definitions	of	AKI	
used	in	many	previous	studies	in	the	literature	varied,	making	direct	comparison	
of	 these	 difficult.	 In	 	 2009,	 the	 National	 Confidential	 Enquiry	 into	 Patient	
Outcome	and	Death	(NCEPOD)	(1)	report	identified	significant	deficiencies	in	the	
management	 of	 AKI	 in	 hospitals	 in	 the	 U.K.	 	 This	 led	 to	 the	 development	 and	
implementation	of	strategies	such	as	the	use	of	electronic	results	reporting	to	aid	
early	 AKI	 recognition	 (2).	 	 In	 response	 the	 Royal	 College	 of	 Physicians,	 at	 a	
consensus	conference	in	the	UK,	recommended	the	adoption	of	an	e-alert	system	
to	aid	 in	 the	early	 identification	of	AKI	(3).	 	Based	on	a	presumption	that	early	
identification	may	help	raise	standards	of	care	and	improve	patient	outcomes,	an	
automated	 real	 time	 e-alert	 system	 for	 AKI	 based	 on	 the	 Kidney	 Disease:	
Improving	Global	Outcomes	(KDIGO)	change	in	creatinine	diagnostic	criteria	has	
been	 established	 and	 implemented	 nationally	 across	 all	 areas	 of	 the	 National	
Health	Service	in	Wales.		Using	a	centralised	system	of	data	collection	the	aim	of	
this	 study	 was	 to	 provide	 a	 comprehensive	 characterisation	 of	 the	 base	
incidence	 and	definition	 outcome	 of	 AKI	 identified	 by	 electronic	 alerts	 (AKI),	
and	its	outcome	across	both	primary	and	secondary	care.		
	
Methods	
Setting	
The	National	Health	Service	in	Wales	which	serves	a	population	of	3.06	million	is	
organised	into	seven	Local	Health	Boards	(Supplementary	Figure	1).		Data	were	
collected	in	all	health	boards.		The	study	was	approved	under	Service	Evaluation	
Project	Registration.			
Development	of	Electronic	Reporting	System	
The	 all	 Wales	 Laboratory	 Information	 Management	 System	 (LIMS),	
(InterSystems	 TrakCare	 Lab)	 in	 real	 time	 automatically	 compares	 measured	
creatinine	values	on	an	 individual	patient	 against	previous	 results,	 to	 generate	
alerts	 (Supplementary	 Figure	 2),	 based	 on	KDIGO	AKI	 criteria	 (Supplementary	
Table	 1).	 	 The	 definition	 of	 AKI	 therefore	 relies	 on	 creatinine	 but	 not	 urine	
output.			A	summary	of	the	“rules”	are	shown	in	Supplementary	Table	2	and	each	
e-alert	code	together	with	the	comment	which	accompanies	the	e-alert	is	shown	
in	 Supplementary	 Table	 3.		 Any	 patient	 presenting	 with	 AKI	 but	 without	 a	
measurement	 of	 renal	 function	 in	 the	 previous	 365	 days	will	 therefore	 not	 be	
included	in	the	study.		
Data	Collection	
Prospective	data	was	collected	for	all	cases	of	adult	(≥18yrs	of	age)	AKI	in	Wales	
between	March	2015	and	August	2015.	 	Clinical	location,	patient	age,	AKI	stage	
and	 the	 rule	 under	which	 the	 AKI	 alert	 was	 generated	was	 collected	 together	
with	all	measurements	of	renal	function	for	up	to	90	days	following	the	AKI	alert.	
An	incident	AKI	episode	was	defined	as	90	days	i.e.	any	AKI	e-alert	for	the	same	
patient	 within	 90	 days	 the	 incident	 alert	 was	 not	 considered	 a	 new	 episode.		
Peak	AKI	 stage	was	 assigned	by	 comparing	 the	highest	 serum	creatinine	 (SCr)	
value	during	an	AKI	incident	episode	with	the	baseline	SCr	of	the	incident	alert.	
To	 prevent	 inclusion	 of	 known	 patients	 receiving	 renal	 replacement	 therapy,	
alerts	transmitted	by	patients	from	a	renal,	renal	transplant,	or	dialysis	setting,	
and	 by	 patients	 who	 had	 a	 previous	 blood	 test	 in	 a	 dialysis	 setting	 were	
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excluded.		All	incident	patients	with	AKI	alerted	for	the	first	time	in	a	non-renal	
location	prior	to	transfer	to	the	regional	renal	unit.			
Incidence	rate	was	calculated	using	Mid-2013	Office	for	National	Statistics	(ONS)	
Population	Estimates.	Patients	 for	whom	the	 first	e-alert	was	generated	 from	a	
creatinine	value	measured	in	primary	care	were	classified	as	primary	care	AKI.		
All	patients	for	which	the	first	alert	was	issued	during	a	hospital	admission	who	
also	had	a	normal	SCr	value	generated	in	a	hospital	setting	within	the	preceding	
seven	 days	were	 defined	 as	 Hospital	 acquired	 (HA)-AKI.	 Patients	 alerting	 in	 a	
non-inpatient	 setting	 (including	 Accident	 and	 Emergency/Acute	 assessment	
units)	 and	 not	 alerting	 in	 primary	 care	 were	 classified	 as	 non-primary	 care	
community	 acquired	 (CA)-AKI.	 	 Primary	 care	 and	 non-primary	 care	 CA-AKI	
therefore	collectively	represent	CA-AKI.		
Hospitalization	of	CA-AKI	was	defined	as	 first	or	second	measurement	of	 renal	
function	 in	 an	 inpatient	 setting	 (within	 7	 days)	 following	 the	 alert.	 	 Mortality	
data	were	collected	from	the	Welsh	Demographic	Service	(WDS).	Patients	were	
censored	 at	 1	 year	 for	 survival	 analysis.	 Renal	 outcome	 analysis	 required	
patients	to	have	90	day	follow	up	data	available	and	included	only	those	patients	
surviving	 at	 this	 time	 point.	 	 Linear	 regression	 analysis	 of	 renal	 outcome	
included	 surviving	 and	 non-surviving	 patients.	 Non-recovery	 from	 an	 AKI	
episode	was	defined	as	achievement	of	a	serum	creatinine	(SCr)	value	closest	to	
and	within	90	days	still	consistent	with	the	definition	of	AKI	 in	comparisons	to	
baseline	SCr	values.	Pre-existing	chronic	kidney	disease	(PeCKD)	was	defined	as	
an	 eGFR	 (calculated	by	CKDEpi	 eGFR	 formula	 (4))	<60ml/min/1.73m2	 derived	
from	the	baseline	SCr.	 	A	worsening	eGFR	was	calculated	using	 the	eGFR	value	
closest	to	and	within	90	days	and	was	defined	by	a	decline	from	baseline	eGFR	of	
>15%	or	>5ml/min/1.73m2	(5).	
The	Welsh	Index	of	Multiple	deprivation	is	Welsh	Government’s	official	measure	
of	 relative	 deprivation.	 	 This	 generates	 a	 rank	 (WIMD	 score)	 for	 1,909	 lower	
super	 output	 geographical	 areas	 (LSOAs)	 in	 Wales	 based	 on	 eight	 domains;	
Income,	Employment,	Health,	Education,	Access	 to	Services,	Community	Safety,	
Physical	 Environment,	 Housing	 (6).	 Patients	 were	 georeferenced	 to	 a	 LSOA	 of	
residence,	and	ranked	according	to	WIMD	score.	Ranked	data	were	categorised	
into	percentiles,	with	percentile	1	the	most	deprived	and	percentile	100	the	least	
deprived.	Patients	were	aggregated	to	their	geographic	area	(LSOA	of	residence),	
and	 incidence	 of	 AKI	 was	 calculated	 using	 the	 total	 adult	 population	 in	 each	
LSOA	derived	from	Mid-2013	ONS	Population	Estimates.	
Statistical	 analysis	was	 carried	out	using	SPSS	 software,	 version	20	 (SPSS,	 Inc.,	
Chicago,	IL).	Student’s	t	test	was	used	for	analysis	of	normally	distributed	data.	
Categorical	data	were	 compared	using	a	Pearson	chi-squared	 test.	Multivariate	
Cox	 proportional	 hazard	 modelling	 was	 used	 to	 analyze	 patient	 survival.	 	 P	
values	less	than	0.05	were	considered	statistically	significant.		
	
Validation	
The	 diagnostic	 accuracy	 was	 determined	 by	 manually	 checking	 baseline	
creatinine	value	for	a	sample	of	200	patients	distributed	across	each	“rule”	and	
“e-alert	 Code”,	 and	 across	 two	 Local	 Health	 Boards	 (LHBs).	 	 All	 the	 e-alerts	
generated	conformed	to	the	mathematical	definition	of	AKI.			
When	known	dialysis	patients	were	not	identified	as	such	by	the	request	through	
the	“location	code”	a	proportion	of	known	dialysis	patients	generated	an	AKI	e-
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alert.	 	 This	 was	 only	 applicable	 to	 ABS1,	 ABS2	 and	 DELTA1	 codes	
(Supplementary	Table	3).	 	For	ABS1	codes	89%	of	 flagged	patients	were	know	
dialysis	patients.		In	total	105	patients	were	flagged	by	this	code.		These	were	all	
excluded	 from	 the	 analysis,	 and	 therefore	11%	of	 the	 cohort	 identified	by	 this	
code	 (12	patients)	with	probable	AKI	were	excluded	 from	 the	overall	 analysis.		
For	 ABS2	 code,	 26%	 of	 patients	were	 dialysis	 patients.	 	 ABS2	 accounted	 for	 a	
total	of	562	patients.	These	have	been	included	in	the	analysis	and	therefore	by	
extrapolation	 146	 likely	 dialysis	 patients	 are	 included	 in	 the	 analysis.	 	 For	 the	
DELTA1	 code	 60%	 of	 those	 flagged	 and	with	 a	 creatinine	 of	 >4.5mg/dL	were	
dialysis	 patients.	 	 In	 total	 89	 patients	 were	 flagged	 by	 this	 code	 and	 had	 a	
creatinine	of	>4.5mg/dL.		These	were	excluded,	and	therefore	40%	of	the	cohort	
identified	by	 this	 code	 (36	patients)	with	probable	AKI	were	excluded.	 	 	Using	
these	criteria	results	in	a	false	negative	rate	of	0.27%	(exclusion	of	AKI	patients)	
and	a	false	positive	rate	of	0.83%	(inclusion	of	known	dialysis	patients).		
	
Results	
Incidence	and	Demographics	(Table	1)	
We	observed	a	total	of	31,601	alerts.		The	majority	(62.9%)	of	patients	generated	
only	 one	 alert.	 Of	 those	 patients	 who	 triggered	 multiple	 e-alerts,	 18.5%	
generated	 2	 alerts,	 8.3%	 3	 alerts,	 4.2%	 4	 alerts,	 2.1%	 5,	 1.3%	 6,	 with	 the	
remainder	generating	between	7-27	alerts.		Only	2.8%	of	incident	episodes	were	
the	result	of	a	second	episode	from	the	same	patient.	
The	 alerts	 generated	 represent	17,689	 episodes	of	AKI.	 This	 translates	 into	 an	
incidence	of	AKI	of	577/100,000	population	over	the	six-month	time	frame,	and	
1.2	cases	per	100	person-years.	The	majority	(78.7%)	of	episodes	were	classified	
as	AKI1	at	presentation,	with	14.3%	AKI2	and	7.0%	AKI3.		23.7%	of	Stage	1	and	
Stage	2	episodes	progressed	to	a	higher	peak	AKI	stage	relative	to	the	 incident	
AKI	alert	stage.	 	15.1%	(944)	and	9.0%	(562)	of	AKI	stage	1	progressed	to	AKI	
stages	2	and	3	respectively,	and,	21.8%	(247)	of	AKI	stage	2	progressed	to	AKI	
stage	3.			
Community	acquired	and	Hospital	acquired	AKI	
The	distribution	of	 e-alerts	by	 the	 location	 in	which	 the	alert	was	generated	 is	
shown	 in	 figure	1A.	CA-AKI	and	HA-AKI	accounted	 for	49.3%	and	41.2%	of	 all	
alerts	respectively.		The	remaining	9.5%	of	alerts	were	generated	in	an	inpatient	
setting	 but	 as	 no	 results	 were	 available	 for	 the	 previous	 7	 days	 it	 was	 not	
possible	to	confidently	classify	these	as	either	CA-	or	HA-AKI.		For	both	AKI	in	the	
community	and	acquired	in	hospital	the	overwhelming	majority	was	AKI1.		
The	distribution	of	clinical	locations	for	both	non-primary	care	CA-AKI	and	HA-
AKI	alerts,	stratified	by	AKI	stage,	is	shown	in	figure	1B&C	(and	Supplementary	
Tables	 4	 &	 5).	 	 The	 majority	 (53%)	 of	 AKI	 acquired	 in	 a	 non-primary	 care	
community	setting	is	first	detected,	in	the	Accident	and	Emergency	department.	
For	 Hospital	 acquired	 AKI,	 the	 largest	 single	 cohort	 is	 “acquired”	 in	 a	 General	
medical	inpatient	setting	(25%),	followed	closely	by	the	combination	of	general	
surgical	 and	 trauma/orthopaedics	 which	 accounts	 for	 24%	 of	 all	 hospital	
acquired.			
For	 community	 acquired	 incident	 AKI	 episodes,	 30.6%	 were	 generated	 by	 an	
alert	 issued	 to	 primary	 care	 which	 represents	 14.6%	 of	 all	 the	 incident	 AKI	
episodes.	 	The	remainder	of	CA-AKI	was	accounted	for	by	patients	alerting	in	a	
non-inpatient	 setting	 (including	 Accident	 and	 Emergency/Acute	 assessment	
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units)	but	excluding	primary-care.	 	Primary	care	AKI	e-alerts	were	 followed	by	
hospital	 admission	 in	 31%	 of	 cases	 (figure	 2A).	 	 For	 primary	 care	 CA-AKI,	
admission	was	associated	with	greater	severity	of	renal	injury,	with	26%	of	AKI1	
admitted	 compared	 to	 42%	 of	 AKI2	 and	 56%	 of	 AKI3.	 	 Non-primary	 care	
community	 AKI	 e-alerts	were	 followed	 by	 hospital	 admission	 in	 71%	 of	 cases	
(figure	2B).			For	this	group	admission	to	hospital	was	not	related	to	AKI	severity.		
There	was	 a	 positive	 relationship	 between	 the	 time	 to	 repeat	measurement	 of	
renal	 function	 and	 hospitalization	 with	 a	 significantly	 longer	 mean	 time	 for	
patients	 not	 hospitalised	 from	 both	 the	 primary	 care	 CA-AKI	 (7.4±13.8	 vs.	
11.9±14.1	days,	p<0.0001)	and	non-primary	care	CA-AKI	(2.7±7.6	vs.	11.1±16.2	
days,	p<0.0001).		In	non-hospitalised	CA-AKI	at	the	time	of	re-testing	18.2%	had	
a	further	elevation	of	serum	creatinine	(compared	to	40.9%	of	CA-AKI	who	were	
hospitalised).		Of	those	CA-AKI	not	diagnosed	in	primary	care,	19.9%	of	patients	
had	a	measurement	of	serum	creatinine	(that	did	not	generate	an	e-alert)	in	the	
preceding	30	days.			
Regional	variations:	
The	geographical	variation	of	AKI	incidence	is	shown	in	Table	1.		The	low	overall	
incidence	 in	 Powys	 and	 the	 higher	 incidence	 in	 Hywel	 Dda	 likely	 reflect	 the	
organisation	 of	 health	 care,	 with	 no	 secondary	 care	 services	 in	 Powys.	 	 Its	
population	 is	 served	 predominantly	 by	 hospital	 services	 in	 the	 neighbouring	
Hywel	 Dda	 health	 board	 (a	 smaller	 proportion	may	 access	 hospital	 service	 in	
English	hospitals	 for	which	we	have	no	data).	 	 The	high	 incidence	 in	Cwm	Taf	
occurs	 in	both	Hospital-acquired	and	Community-acquired	groups.	 	This	board	
serves	 the	 most	 socially	 deprived	 population	 in	 the	 Principality.	 	 The	
relationship	 between	 incidence	 of	 AKI	 and	 patient	 socio-economic	 status	 is	
shown	in	Figure	3.		There	was	a	strong	negative	correlation	between	ranking	by	
WIMD	score	and	the	incidence	of	AKI	(r=-0.91,	95%	CI	-0.94	to	-0.87	p<0.001).		
Significance	of	an	episode	of	AKI	
Mortality:	 90-day	 mortality	 for	 AKI	 is	 shown	 in	 figure	 4.	 	 Overall	 90-day	
mortality	 was	 25.6%.	 	 Mortality	 was	 significantly	 higher	 (p<0.001)	 in	 HA-AKI	
compared	 to	 CA-AKI	 (Figure	 4A).	 	 For	 CA-AKI	 mortality	 (Figure	 4B&C)	 was	
significantly	higher	in	the	hospitalised	cohort	(p<0.001)	and	in	non-primary	care	
CA-AKI	(p<0.001).		Cox	regression	proportional	hazard	modelling	analysis	(with	
follow	up	data	up	 to	and	 including	12	months)	demonstrated	higher	hazard	of	
death	associated	with	older	age	(HR	1.03,	95%	CI,	1.029-1.034),	more	severe	AKI	
at	presentation	(AKI	2/3	versus	AKI;	HR	1.43,	95%	CI,	1.34-1.54),	and	peak	AKI	
stage	 (AKI	 2/3	 versus	AKI1;	HR	2.36,	 95%	CI,	 2.20-2.53).	 	 Increased	 hazard	 of	
death	was	associated	with	non-primary	care	CA-AKI	(un-adjusted	HR	1.77,	95%	
CI,	 1.59-1.97;	 adjusted	 HR	 1.65,	 95%	 CI,	 1.48-1.84,	 p<0.001)	 and	 HA-AKI	 (un-
adjusted	 HR	 2.04,	 95%	 CI,	 1.83-2.26:	 adjusted	 HR	 1.98,	 95%	 CI,	 1.78-2.19;	
p<0.001)	compared	with	primary	care	CA-AKI.	 	For	CA-AKI	hospitalization	was	
also	 associated	with	 increased	 hazards	 of	 death	 (HR,	 1.31;	 95%	 CI,	 1.23-1.39;	
p<0.001).			
Renal	 Outcomes:	 The	 relationship	 between	 the	 incident	 AKI	 e-alert	 and	
subsequent	 renal	 function	 is	 shown	 in	 figure	5.	Significantly	more	patients	did	
not	recover	their	renal	function	following	an	episode	of	HA-AKI	compared	with	
CA-AKI	 (14.6%	vs.	7.9%	p<0.001).	 	 In	 contrast	more	patients	with	CA-AKI	and	
pre-existing	CKD	were	likely	to	have	worsening	renal	function	following	the	AKI	
episode,	 than	 following	 HA-AKI	 (42.5%	 vs.	 35.9%,	 p=0.002).	 For	 the	 whole	
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cohort,	more	severe	AKI	at	presentation	(AKI	2/3	versus	AKI1;	HR	1.82	95%	CI,	
1.64-2.03)	and	peak	AKI	stage	(AKI	2/3	versus	AKI1;	HR	3.98,	95%	CI,	3.49-4.54)	
were	associated	with	non-recovery	of	renal	function.			
For	 CA-AKI	 picked	 up	 in	 primary	 care	 (Figure	 5B),	 non-recovery	 of	 renal	
function	 was	 significantly	 higher	 than	 non-primary	 care	 CA-AKI	 (p<0.001).		
Similarly,	AKI	detected	in	primary	care	was	associated	with	a	greater	likelihood	
of	 developing	 an	 eGFR	<60ml/min/1.73m2	 for	 the	 first	 time	 (p<0.001),	 and	 of	
those	 patients	with	 pre-existing	 CKD,	 patients	with	 primary	 care	 CA-AKI	were	
significantly	 more	 likely	 to	 experience	 a	 worsening	 eGFR	 (p<0.001).	 	 The	
relationship	between	admission	to	hospital	and	renal	outcome	for	all	community	
acquired	AKI	groups	is	shown	in	figure	5C.		Hospitalization	was	associated	with	
better	outcome	in	terms	of	recovery	from	the	acute	episode	(p<0.001),	a	 lower	
proportion	of	patients	developing	an	eGFR	<60ml/min/1.73m2	for	the	first	time	
and	less	patients	with	pre-existing	CKD	experiencing	worsening	eGFR	(p<0.001	
for	 both	 parameters).	 	 By	 linear	 regression	 better	 acute	 outcome	 adjusted	 for	
both	 incident	 and	peak	AKI	 stage	was	also	associated	with	hospitalization	 (HR	
1.23;	95%	CI	1.16-1.29;	p<0.001).			
	
Discussion	
The	majority	 of	 publications	 of	 large	 series	 characterising	 AKI	 rely	 on	making	
and	 recording	 an	 accurate	 diagnosis	 of	 AKI	 through	 hospital	 coding	 or	
retrospective	 review	 of	 hospital	 records	 (7-10).	 	 Although	 providing	 essential	
information	 on	 the	 epidemiology	 of	 AKI	 there	 is	 significant	 potential	 for	 AKI	
episodes	 to	 be	 missed	 resulting	 in	 underestimation	 of	 true	 incidence	 of	 AKI.		
There	 are	 publications	 which	 have	 sought	 to	 overcome	 this	 via	 a	 biochemical	
identification	 of	 AKI	 as	 a	 trigger	 to	 identify	 the	 patients.	 	 These	 are	 however,	
either	 single	 centre	hospital	 based	 studies	 (11,	 12),	 or	 reliant	 on	 an	 electronic	
alert	which	was	not	based	on	an	internationally	agreed	AKI	definition	(13).	 	To	
address	 this,	 we	 used	 a	 national	 data	 set	 to	 provide	 a	 comprehensive	
characterisation	 of	 the	 incidence	 of	 electronic	 AKI	 alerts,	 and	 the	 subsequent	
clinical	course.			
The	first	key	finding	in	this	study	is	the	high	incidence	of	AKI.	Previous	studies	
have	 suggested	 an	 annual	 incidence	 of	 200-300/100	 000	 in	 high	 income	
countries	 (14).	 	 The	 use	 of	 an	 alert	 based	 system	 for	 patient	 identification	
therefore	overcomes	systematic	under-reporting	of	AKI	associated	with	previous	
studies.		The	study	also	demonstrates	a	significant	association	of	AKI	with	renal	
function	at	90	days	following	the	incident	episode.		For	the	whole	cohort	of	over	
17,000	patients,	more	than	a	quarter	of	the	population	either	developed	an	eGFR	
<60ml/min/1.73m2	 for	 the	 first	 time	 –	 which	 may	 be	 indicative	 of	 the	
development	of	de	novo	CKD,	or	experienced	worsening	of	pre-existing	CKD	after	
the	 incident	 AKI	 e-alert	 which	may	 impact	 on	 the	 need	 to	 plan	 for	 long	 term	
provision	of	renal	replacement	therapy.			
In	 contrast	 to	 studies	 describing	 HA-AKI,	 less	 is	 known	 regarding	 the	
characterisation	of	CA-AKI.		Published	studies	in	are	in	the	main	reliant	on	small	
patient	numbers	and	due	to	geographical	differences	in	disease	patterns	may	not	
be	directly	applicable	to	all	populations	(15-17).			The	findings	in	this	manuscript	
are	however	consistent	with	our	previous	publications	(5,	18)	and	other	recent	
smaller	 studies	 from	 Scotland	 (19)	 and	Kentucky	 (20)	 demonstrating	 that	 CA-
AKI	 represents	 a	 significant	 proportion	 of	 all	 AKI.	 	 The	 outcome	 for	 CA-AKI	
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defined	by	an	eALERT	is	better	than	HA-AKI.	 	This	needs	to	be	qualified	by	the	
observation	a	significant	proportion	of	patients	with	CA-AKI	are	not	admitted	to	
hospital,	 and	 which	 therefore	 are	 not	 reported	 upon	 in	 the	 majority	 of	
publications	which	characterize	the	nature	and	outcome	of	CA-AKI.		
In	this	study	there	is	a	significant	mortality	following	an	AKI	e-alert.		Mortality	is	
clearly	higher	 in	the	cohort	of	patients	admitted	to	hospital,	however	 it	of	note	
that	even	in	CA-AKI	patients	who	are	not	admitted	to	hospital	there	is	a	90-day	
mortality	of	10-15%,	suggesting	that	even	in	this	group	for	which	admission	may	
not	be	appropriate	or	desirable	that	AKI	is	a	marker	of	frailty.	 	In	the	surviving	
patients	it	 is	also	of	note	that	“non-admission”	is	associated	with	a	significantly	
worse	renal	outcome.		Whilst	in	some	cases	“non-admission”	may	be	appropriate	
and	reflect	a	conscious	decision,	e.g.	in	the	setting	of	palliative	care,	our	previous	
published	 data	 (5,	 18)	 and	 the	 data	 on	 time	 to	 repeat	 measurement	 of	 renal	
function	 in	 this	 study	 suggest	 that	 “non-admission”	 is	 at	 least	 in	part	 is	due	 to	
lack	of	recognition	of	the	significance	of	the	alert.		Our	data	is	however	consistent	
with	 the	 recent	 report	 of	 Sawheny	 in	which	non-admitted	AKI	whilst	 having	 a	
lower	mortality	was	associated	with	greater	non-recovery	of	renal	function	(21).		
On	a	national	 level	our	data	suggest	regional	variations	in	the	incidence	of	AKI,	
with	two	areas	in	particular	highlighted	as	outliers.		The	very	small	incidence	in	
Powys	likely	reflects	the	rural	nature	of	the	area	with	the	population	relying	on	
hospitals	 in	neighbouring	 areas.	 	 Even	 accepting	 this	 discrepancy	 the	 reported	
incidence	 is	very	 low.	 	Access	 to	hospital	 facilities,	and	renal	 services,	has	 long	
been	established	as	a	factor	influencing	the	reported	incidence	of	CKD	(22,	23),	
and	it	is	interesting	to	speculate	that	the	same	may	be	true	in	terms	of	awareness	
of	AKI.	 	The	second	notable	exception	in	AKI	 incidence	is	Cwm	Taf.	 	The	Welsh	
Index	of	Multiple	Deprivation	(6),	is	produced	at	a	small	area	level	called	Lower	
Super	Output	Area	(LSOA),	and	is	derived	from	a	broad	range	of	factors.	73	out	of	
the	188	LSOAs	 in	 this	LHB	 (39	per	 cent)	 are	among	 the	most	deprived	 fifth	 in	
Wales.			The	tight	association	of	AKI	incidence	and	WIMD	rank	across	the	whole	
cohort	 supports	 the	 notion	 that	 a	 higher	 prevalence	 of	 AKI	 is	 associated	with	
social	deprivation	as	has	been	previously	described	 for	CKD	(24,	25).	Although	
beyond	 the	scope	of	 this	 study	we	speculate	 that	 this	at	 least	 in	part	 reflects	a	
higher	 incidence	of	 co-morbidities,	which	 are	AKI	 risk	 factors	 (26),	 in	 areas	 of	
social	deprivation.				
Although	this	study	is	to	our	knowledge	the	first	national	study	using	an	e-alert	
based	system	to	characterise	the	magnitude	and	impact	of	AKI,	its	findings	need	
to	 be	 qualified	 by	 its	 limitations.	 	 As	 the	 e-alert	 system	 is	 IT	 driven	 it	 lacks	
“intelligence”	and	therefore	there	is	no	clinical	context	applied.	 	For	this	reason	
the	 variation	 in	 serum	 creatinine	 seen	 in	 dialysis	 patients,	 unless	 specifically	
flagged	by	 location,	 leads	 to	 a	number	of	 false	positives.	 	 In	order	 to	minimise	
this	impact	we	have	excluded	incident	patients	flagged	by	two	codes	(ABS1	and	
DELTA1)	which	will	have	also	excluded	some	patients	with	true	AKI.		The	study	
is	 also	 limited	 in	 that	 any	 patient	 presenting	 with	 AKI	 but	 without	 a	
measurement	 of	 renal	 function	 in	 the	 previous	 365	 days	will	 not	 be	 included.		
Using	an	IT	based	approach	also	precludes	inclusion	of	clinical	information,	such	
as	 patient	 co-morbidity	 and	 linkage	 to	 primary	 care	 data	 sets,	 and	 lacks	 the	
detail	of	the	cause	of	AKI,	the	need	for	RRT,	and	does	not	shed	light	on	the	cause	
of	death.		It	should	also	be	noted	that	the	data	collected	is	for	a	six-month	period	
and	therefore	potential	seasonal	effects	on	incidence	may	be	lost.	 	Although	we	
9 
	
have	collected	data	on	the	development	of	CKD	this	is	limited	by	outcome	data	to	
90	days	only	and	therefore	longer	term	studies	of	follow	up	are	needed	to	truly	
describe	the	association	with	progressive	CKD.		It	should	also	be	noted	that	the	
outcomes	 reported	 in	 our	 study	may	 be	 influenced	 by	 the	 transmission	 of	 the	
alert	 making	 direct	 comparison	 with	 other	 studies	 difficult.	 	 Despite	 these	
limitations	 our	 study	 provides	 the	 first	 large	 scale	 description	 of	 AKI,	 using	 a	
creatinine	based	electronic	AKI	alert.		
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Table	1.	Incidence/demography	of	AKI	
Variable	 	 	 	 	
n/100,000	population	(n)	 577(17,689)	 	 	 	
AKI	Severity,	%	(n)	 	 	 	 	
Stage	1	 78.7(13,922)	 	 	 	
Stage	2	 14.3	(2,522)	 	 	 	
Stage	3	 7.0	(1,245)	 	 	 	
AKI	Rule,	%	(n)	 	 	 	 	
Rule	1	 9.9	(1,753)	 	 	 	
Rule	2	 27.1	(4,799)	 	 	 	
Rule	3	 63.0	(11,137)	 	 	 	
Clinical	Location,	%	(n)	 	 	 	 	
Hospital	 41.2	(7,288)	 	 	 	
Community	 49.3	(8,724)	 	 	 	
	 All	AKI	 HA-AKI	 CA-AKI	 	
Health	Board,	n/100,000	population	(n)	 	 	 	 	
Abertawe	Bro	Morgannwg	UHB	 549	(2,857)	 396.9	 216.6	 	
Aneurin	Bevan	UHB	 550	(3,185)	 189.9	 265.9	 	
Betsi	Cadwaladr	UHB	 564	(3,906)	 219.1	 282.2	 	
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Cardiff	and	Vale	UHB	 513	(2,457)	 247.7	 239.1	 	
Cwm	Taf	UHB	 814	(2,402)	 313.8	 429.0	 	
Hywel	Dda	UHB	 693	(2,659)	 258.4	 392.5	 	
Powys	THB	 60	(80)	 5.3	 46.0	 	
	 All	AKI	 AKI	Stage	1	 AKI	Stage	2	 AKI	Stage	3	
Mean	age	±SD	(yr)	 71.1	±17.0	 71.0	±17.3	 71.8	±15.9	 70.5	±15.9	
Sex,	%	(n)	 	 	 	 	
Male	 46.9	(8,285)	 46.1	(6,407)	 46.4	(1,171)	 56.8	(707)	
Female	 53.1	(9,388)	 53.9	(7,499)	 53.6	(1,351)	 43.2	(538)	
Pre-existing	CKD,	%	(n)	 41.9	(6,877)	 38.5	(5,354)	 34.5	(870)	 52.5	(653)	
Mean	baseline	SCr	(mg/dL)	 1.0	 1.0	 0.9	 1.4	
Mean	baseline	eGFR	(ml/min/1.73m²)	 71.6	 72.0	 74.4	 61.7	
Mean	alert	SCr	(mg/dL)	 1.8	 1.5	 2.1	 4.7	
Mean	peak	SCr	(mg/dL)	 2.3	 1.9	 2.5	 5.3	
Data	on	patient	sex	were	missing	for	16	cases	and	excluded	from	analysis	of	the	
sex	variable.	Baseline	eGFR	data	were	missing	for	24	cases	and	excluded	from	
analysis	of	the	Pre-existing	CKD	variable.	UHB,	University	Health	Board;	THB,	
Teaching	Health	Board;	HA-AKI,	Hospital	acquired	AKI;	CA-AKI,	Community	
acquired	AKI;	CKD,	chronic	kidney	disease;	SCr,	Serum	creatinine.	
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Figure	Legends	
Figure	 1:	 Source	 of	 incident	 AKI	 e-alerts:	 [A]	 Distribution	 of	 AKI	 stages	 for	
hospital	 acquired	 AKI	 (HA-AKI)	 and	 community	 acquired	 AKI	 (CA-AKI).	 [B]	
Percentage	and	number	of	non-Primary	Care	CA-AKI	patients,	dividing	according	
to	 clinical	 specialty	and	AKI	 stage.	Clinical	 specialty	data	were	missing	 for	289	
cases	 and	 excluded	 from	 analysis.	 [C]	 Percentage	 and	 number	 of	 HA-AKI	
patients,	dividing	according	to	clinical	specialty	and	AKI	stage.	Clinical	specialty	
data	were	missing	for	692	cases	and	excluded	from	analysis.		
Figure	 2:	 Hospitalization	 of	 community	 acquired	 AKI:	 [A]	 Percentage,	 average	
age,	and,	percentage	with	pre-existing	CKD	(shaded	area	of	each	bar),	of	primary	
care	 AKI	 (PC-AKI)	 patients	 that	 were	 hospitalised,	 dividing	 according	 to	 AKI	
stage	(Total	number	of	patients:	Stage	1,	1,531;	Stage	2,	255;	Stage	3,	175).	 [B]	
Percentage,	average	age,	and,	percentage	with	pre-existing	CKD	(shaded	area	of	
each	bar),	of	non-primary	care	AKI	(non-PC-AKI)	patients	that	were	hospitalised,	
dividing	according	to	AKI	stage	(Total	number	of	patients:		Stage	1,	3,727;	Stage	
2,	889;	Stage	3,	542).	PeCKD,	pre-existing	chronic	kidney	disease.	
Figure	 3:	 	 Relationship	 between	 incidence	 of	 AKI	 and	 the	 index	 of	 social	
deprivation.	221	cases	with	missing	postcode	data	were	excluded	from	analysis;	
121	 cases	 with	 English	 postcodes	 were	 excluded	 from	 analysis.	WIMD,	Welsh	
Index	 of	 Multiple	 deprivation	 where	 percentile	 is	 the	 most	 deprived	 and	
percentile	100	is	the	least	deprived.	
Figure	4:	90-day	mortality	associated	with	incident	AKI	e-alerts:	[A]	Percentage	
of	AKI	patients	that	died,	dividing	according	to	place	of	identification	of	AKI.	[B]	
Percentage	of	CA-AKI	patients	that	died,	dividing	according	to	hospitalization.	[C]	
Percentage	 of	 CA-AKI	 patients	 that	 died,	 dividing	 according	 to	 place	 of	
identification	 of	 AKI.	 Mortality	 was	 significantly	 higher	 for	 all	 the	 “admitted	
groups”	 (p<0.001	 compared	 to	 non-admitted	 groups).	 Mortality	 rates	 were	
comparable	in	the	admitted	non-primary	care	CA-AKI	and	HA-AKI	groups,	which	
were	 significantly	 higher	 than	 in	 the	 primary	 care	 AKI	 admitted	 cohort	
(p=0.009).	Number	of	patients	with	data	available	indicated	in	parentheses	in	x	
axis.	Shading	indicates	the	proportion	of	patients	that	died	by	AKI	Stage.	
Figure	 5:	 Renal	 outcome	 following	 AKI	 e-alerts:	 [A]	 Renal	 outcome	 of	 AKI	
patients,	dividing	according	to	place	of	 identification	of	AKI.	Of	 the	patients	 for	
which	90-day	follow	up	data	were	available,	1,841	(1,047,	hospital	acquired	AKI	
(HA-AKI);	794,	 community	acquired	AKI	 (CA-AKI))	had	died	within	 the	90	day	
follow	up	period	and	were	excluded	from	analysis.	[B]	Renal	outcome	of	CA-AKI	
patients,	dividing	according	to	place	of	 identification	of	AKI.	Of	 the	patients	 for	
which	 90-day	 follow	 up	 data	were	 available,	 794	 (121,	 Primary	 Care	 acquired	
AKI	 (PC-AKI);	 673,	 non-primary	 care	 acquired	 AKI	 (non-PA-AKI))	 had	 died	
within	 the	 90	 day	 follow	 up	 period	 and	 were	 excluded	 from	 analysis.	 ‘Non-
recovery’	is	expressed	as	a	percentage	of	the	whole	cohort	and	was	defined	as	a	
serum	creatinine	(SCr)	value	at	90	days	following	the	AKI	episode	still	in	keeping	
with	the	definition	of	AKI	in	comparisons	to	baseline	SCr	values.	‘No	PeCKD	and	
eGFR	 <60’,	 and,	 ‘PeCKD	 and	worsening	 eGFR’	 are	 expressed	 as	 percentages	 of	
their	respective	PeCKD	(pre-existing	chronic	kidney	disease)	cohorts.	 [C]	Renal	
outcome	of	CA-AKI	patients,	dividing	according	to	hospitalization.	Of	the	patients	
for	 which	 90-day	 follow	 up	 data	 were	 available,	 794	 (599,	 hospitalised	
community	 acquired	 AKI	 (Hosp.	 CA-AKI);	 195,	 non-hospitalised	 community	
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acquired	AKI	(Non-hosp.	CA-AKI))	had	died	within	the	90	day	follow	up	period	
and	were	excluded	from	analysis.	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Supplementary	Table	1.		Staging	of	AKI	
Stage	 Serum	creatinine	
1	 1.5	-1.9	times	baseline	or	≥26µmol/L	
increase	
2	 2.0-2.9	times	baseline		
3	 3.0	times	baseline	or	≥354µmol/L	
	
Supplementary	Table	2.		E-alert	rules.		
Rule	 Description	 Associated	alert	
1	 >26µmol/L	increase	in	creatinine	
in	previous	48	hours	
Acute	Kidney	Injury	alert:	rising	
creatinine	within	last	48	hours	
2	 >50%	increase	in	creatinine	in	
previous	7	days	
Acute	Kidney	Injury	alert:	rising	
creatinine	within	last	7	days	
3	 >50%	increase	in	creatinine	
against	median	result	for	previous	
8-365	days	
Acute	Kidney	Injury	alert	–	
creatinine	increase	over	baseline	
value	
	 	 	
	
	Supplementary	Table	3.	AKI	e-alert	codes	and	their	corresponding	triggers,	
AKI	rules,	AKI	stages	
E-alert	
code	
Trigger	 AKI	
rule	
AKI	
stage	
DELTA1	 D>26µmol/L	and	no	other	rule	triggered	 1	 1	
ABS1	 C1/RV1>C1/RV2	and	C1/RV1≥1.5	and	
C1>354µmol/L	
2	 3	
ABS2	 C1/RV2>C1/RV1	and	C1/RV2≥1.5	and	
C1>354µmol/L	
3	 3	
R1AKI1	 C1/RV1>C1/RV2	and	C1/RV1≥1.5	and	
C1/RV1<2.0	
2	 1	
R1AKI2	 C1/RV1>C1/RV2	and	C1/RV1≥2.0	and	
C1/RV1<3.0	
2	 2	
R1AKI3	 C1/RV1>C1/RV2	and	C1/RV1≥3.0	 2	 3	
R2AKI1	 C1/RV2>C1/RV1	and	C1/RV2≥1.5	and	 3	 1	
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C1/RV2<2.0	
R2AKI2	 C1/RV2>C1/RV1	and	C1/RV2≥2.0	and	
C1/RV2<3.0	
3	 2	
R2AKI3	 C1/RV2>C1/RV1	and	C1/RV2≥3.0	 3	 3	
D,	Difference	between	C1	and	lowest	previous	serum	creatinine	(SCr)	value	
within	48	hours;	C1,	Index	SCr	value	(current	result	entered	and	authorised	on	
the	LIMS);	RV1,	Reference	value	1,	lowest	SCr	value	existing	within	previous	7	
days;	RV2,	Reference	value	2,	median	of	SCr	values	existing	within	previous	8-
365	days.	
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Supplementary	Table	4.		Specialties	labelled	‘Other’	in	Figure	1C	
Specialty	
N	AKI	
episodes	
%	
Thoracic	Medicine	 85	 1.45%	
Medical	Oncology	 82	 1.40%	
Rheumatology	 65	 1.11%	
Nephrology	 54	 0.92%	
Endocrinology	 45	 0.77%	
GP	Other	 30	 0.51%	
Cardiothoracic	Surgery	 29	 0.50%	
Rehabilitation	 27	 0.46%	
Gynaecology	 25	 0.43%	
Chemical	Pathology	 25	 0.43%	
Clinical	Pharmacology	and	
therapeutics	
24	 0.41%	
Anaesthetics	 17	 0.29%	
Palliative	Medicine	 15	 0.26%	
Pain	Management	 14	 0.24%	
Old	Age	Psychiatry	 14	 0.24%	
Obstetrics	(for	patients	using	a	
bed)	
13	 0.22%	
Dermatology	 13	 0.22%	
Mental	Illness	 12	 0.21%	
ENT	 10	 0.17%	
Paediatrics	 9	 0.15%	
Ophthalmology	 6	 0.10%	
Neurology	 6	 0.10%	
Plastic	Surgery	 6	 0.10%	
Oral	Surgery	 5	 0.09%	
Not	Known	 5	 0.09%	
Obstetrics	PN	(outpatients)	 4	 0.07%	
Haematology	(non-clinical)	 4	 0.07%	
Arts	therapist	 4	 0.07%	
Radiology	 4	 0.07%	
Obstetrics	AN	(outpatients)	 3	 0.05%	
Mental	Handicap	 2	 0.03%	
Community	Medicine	 2	 0.03%	
Genito	Urinary	Medicine	 2	 0.03%	
Clinical	Immunology	and	Allergy	 2	 0.03%	
Midwifery	 1	 0.02%	
General	Pathology	 1	 0.02%	
Restorative	Dentistry	 1	 0.02%	
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Supplementary	Table	5.	Specialties	labelled	‘Other’	in	Fig	1D	
Specialty	
N	of	AKI	
episodes	
%	
Haematology	(Clinical)	 135	 2.05%	
Endocrinology	 117	 1.77%	
Rehabilitation	 95	 1.44%	
Obstetrics	(for	patients	using	a	
bed)	
81	 1.23%	
Gynaecology	 79	 1.20%	
Accident	&	Emergency	 62	 0.94%	
Old	Age	Psychiatry	 59	 0.89%	
Nephrology	 59	 0.89%	
GP	Other	 50	 0.76%	
Clinical	Oncology	 47	 0.71%	
Neurosurgery	 27	 0.41%	
Mental	Illness	 23	 0.35%	
Clinical	Pharmacology	and	
therapeutics	
17	 0.26%	
ENT	 16	 0.24%	
Paediatrics	 15	 0.23%	
Medical	Oncology	 12	 0.18%	
Neurology	 9	 0.14%	
Oral	Surgery	 7	 0.11%	
Plastic	Surgery	 7	 0.11%	
Community	Medicine	 6	 0.09%	
Rheumatology	 4	 0.06%	
Dermatology	 4	 0.06%	
Chemical	Pathology	 3	 0.05%	
Clinical	Genetics	 3	 0.05%	
Ophthalmology	 2	 0.03%	
General	Pathology	 2	 0.03%	
Midwifery	 2	 0.03%	
Restorative	Dentistry	 1	 0.02%	
Genito	Urinary	Medicine	 1	 0.02%	
Psychotherapy	 1	 0.02%	
Radiology	 1	 0.02%	
Palliative	Medicine	 1	 0.02%	
Obstetrics	AN	(outpatients)	 1	 0.02%	
Pain	Management	 1	 0.02%	
Mental	Handicap	 1	 0.02%	
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Supplementary	Figure	Legends:	
Supplementary	Figure	1:	Geographical	location	of	Welsh	Local	Health	boards	and	
their	 associated	 descriptive	 demographic	 data.	 UHB,	 University	 Health	 Board;	
tHB,	 Teaching	 Health	 Board;	 DGH,	 District	 General	 Hospital;	 GP,	 General	
Practitioner.	
Supplementary	Figure	2:	Algorithm	for	generating	e-alerts	for	Acute	Kidney	
Injury	based	on	serum	creatinine	(SCr)	changes	with	time.		RV,	Reference	value,	
defined	as	the	SCr	value	with	which	the	index	SCr	value	is	compared;	D,	
difference	between	current	and	lowest	previous	result	within	48	hours;	RI,	
Population	reference	interval.		
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